Skip to main content
    R

    Rapport Therapeutics, Inc. Common Stock (RAPP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $29.57
    +1.24 (+4.38%)

    Market Cap: $1.36B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(6/9)
    Avg Surprise
    -10.76%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.23
    Range$-1.36 - $-1.12
    10 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.01-22.7%
    60d ago$-1.23-0.1%
    30d ago$-1.23-0.1%
    7d ago$-1.23-0.1%
    Current$-1.23
    Revenue Consensus
    $0
    Range$0 - $0
    13 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.16
    Range$-1.58 - $-0.92
    10 analysts
    Revenue Consensus
    $14M
    Range$14M - $14M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.16---
    Sep 26EST
    		-$-1.23---
    Jun 26
    Reported Aug 5
    		$-1.19$-0.93-27.96%Miss-58.7%
    Mar 26
    Reported May 7
    		$-0.42$-0.71+40.85%Beat+38.2%
    Dec 25
    Reported Mar 10
    		$-0.72$-0.67-6.78%Miss-26.3%
    Sep 25
    Reported Nov 6
    		$-0.71$-0.73+2.74%Beat-42.0%
    Jun 25
    Reported Aug 7
    		$-0.75$-0.87+13.79%Beat+55.9%
    Mar 25
    Reported May 8
    		$-0.68$-0.74+8.11%Beat+39.3%
    Dec 24
    Reported Mar 11
    		$-0.57$-0.70+18.57%Beat-
    Sep 24
    Reported Nov 7
    		$-0.50$-0.52+3.85%Beat-
    Jun 24
    Reported Aug 8
    		$-1.70$-0.68-150.00%Miss-
    Mar 24
    Reported May 29
    		$-1.12$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-9.73EV/EBITDAN/A
    Price/FCF-14.45xFCF Yield-6.92%
    Profitability
    Profit Margin0.00%Operating Margin-768.00%
    ROE-40.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio15.72xQuick Ratio15.72x
    Trading Statistics
    Beta1.22Avg Volume467.27K
    52-Week High$52.9352-Week Low$23.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$30.39
    SMA 20$33.01
    SMA 50$41.44
    SMA 200$35.78
    EMA 10$30.61
    EMA 20$33.25
    EMA 50$37.74
    EMA 200$35.64

    MACD

    Line: -3.51Signal: -3.49Hist: -0.01

    ADX

    ADX: 48.6+DI: 11.3-DI: 31.1

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down96.0
    PSAR$32.44

    Bollinger Bands

    Upper Band$40.38
    Lower Band$25.65
    %B Position4461%(Upper)
    Band Width0.27

    RSI (14-Day)

    Oversold
    28.4

    Momentum Oscillators

    Stoch %K10.5
    Stoch %D7.4
    Williams %R-77.0
    ROC (10d)-9.9%
    Momentum-3.26
    CCI (20d)-91.1
    MFI (14d)24.9

    Volatility Measures

    ATR (14d)$2.02(6.8%)
    StdDev (20d)3.68
    Hist Vol71.5%(High)

    Volume Flow

    VWAP$29.57
    OBV25.2M
    AD Line-10.8M
    CMF (20d)-0.107

    Volume Metrics

    Avg Vol (20d)474.8K
    Vol Ratio0.7x
    VWMA (20d)$34.57

    Pivot Points

    R3$30.27
    R2$29.79
    R1$29.06
    Pivot Point$28.58
    S1$27.85
    S2$27.37
    S3$26.64

    Advanced Oscillators

    TSI-51.11
    Ultimate Osc38.8
    KST-299.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$20.00M$0$0$0$0$720,000$0$0$0$0$0
    Cost of Revenue$0$0$265,000$0$0$0$260,000$0$0$0$76,000$0
    Gross Profit$0$20.00M$-265,000$0$0$0$-260,000$0$0$0$-76,000$0
    Operating Expenses$60.81M$44.22M$38.51M$29.99M$29.50M$27.11M$23.52M$21.64M$20.80M$17.09M$14.72M$9.56M
    R&D$51.41M$32.72M$30.26M$22.28M$22.68M$19.57M$17.20M$15.54M$15.69M$12.50M$11.80M$7.58M
    SG&A$9.39M$11.50M$8.25M$7.71M$6.82M$7.54M$6.32M$6.10M$5.11M$4.59M$3.00M$1.98M
    Operating Income$-60,806,000$-24,215,000$-38,509,000$-29,986,000$-29,496,000$-27,108,000$-23,521,000$-21,640,000$-20,800,000$-17,094,000$-14,794,000$-9,564,000
    Interest Income$4.19M$4.36M$4.75M$3.06M$2.76M$3.04M$3.54M$4.10M$2.68M$1.81M$1.38M$856,000
    Interest Expense$0$0$0$0$0$0$0$0$0$5.58M$0$0
    Income Before Tax$-56,615,000$-19,857,000$-33,763,000$-26,925,000$-26,732,000$-24,063,000$-19,980,000$-17,537,000$-18,121,000$-22,669,000$-13,513,000$-8,708,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$6,000$1,000
    Net Income$-56,615,000$-19,857,000$-33,763,000$-26,925,000$-26,732,000$-24,063,000$-19,980,000$-17,537,000$-18,121,000$-22,669,000$-13,519,000$-8,709,000
    EBITDA$-59,654,000$-23,770,000$-39,316,000$-29,526,000$-28,853,000$-26,889,000$-22,701,000$-23,385,000$-21,421,000$-25,310,000$-13,338,000$-9,541,000
    EBIT$-60,806,000$-24,215,000$-38,509,000$-29,986,000$-29,496,000$-27,108,000$-23,521,000$-21,640,000$-20,800,000$-24,484,000$-13,391,000$-9,564,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RAPP

    News

    UBS Initiates Rapport Therapeutics at Buy With $71 Price Target

    UBS has initiated coverage on Rapport Therapeutics with a Buy rating and set a price target of $71. This indicates a positive outlook from UBS on the pharmaceutical company's future performance and stock potential.

    Moomoo•10/15/26•Bullish

    UBS Initiates Rapport Therapeutics at Buy With $71 Price Target

    UBS has initiated coverage on Rapport Therapeutics (RAPP) with a "Buy" rating and set a price target of $71. The stock currently holds an average "Buy" rating from analysts with a mean price target of $62.88. The full...

    Yahoo Finance•10/15/26•Bullish

    Which Brain Pathways Is Rapport Therapeutics Trying to Tune?

    Rapport Therapeutics, a clinical-stage biopharmaceutical company, is developing precision medicines for neurological disorders...

    Kalkine Media•10/11/26•Somewhat-Bullish

    Several Rapport Therapeutics Insiders Sell Shares Sending Potential Negative Signal

    Several insiders at Rapport Therapeutics (NASDAQ:RAPP) have sold shares over the past year, which could signal a potential concern for shareholders. While insider selling doesn't always send a clear message...

    Simply Wall Street•10/11/26•Bearish

    Form 4 Rapport Therapeutics Inc For: 10 October By Investing.com

    This article from Investing.com reports on a Form 4 filing for Rapport Therapeutics Inc. The brief news item indicates a filing related to the company on October 10. No specific details about the Form 4 content are...

    Investing.com Canada•10/11/26•Neutral

    RAPP Valuation and Fair Value

    P/E
    -9.7x
    P/FCF
    -14.4x
    P/B
    3.3x
    See GNG's fair value

    RAPP Profitability: Margins, ROIC and FCF

    Operating margin
    -768.0%
    Net margin
    0.0%
    ROE
    -40.0%
    FCF margin
    -485.7%
    FCF yield
    -6.9%

    RAPP Competitors

    CompanyTicker
    Kalvista Pharmaceuticals IncKALV
    CONMED CorporationCNMD
    Nutex Health IncNUTX
    Omeros CorporationOMER
    AMN Healthcare Services IncAMN
    Mind Medicine IncMNMD
    Pennant Group IncPNTG
    Alpha Tau Medical LtdDRTS

    Sector: Healthcare

    RAPP Analyst Ratings

    Consensus
    Buy
    Analysts
    13
    Strong Buy
    1
    Buy
    12
    Hold
    0
    Sell
    0
    Strong Sell
    0

    RAPP Bull Case vs Bear Case

    Bull case

    • RAPP beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of RAPP's analyst ratings are Buy or Strong Buy.

    RAPP Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    6.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.23
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 3 down

    Frequently Asked Questions About RAPP

    Does RAPP pay dividends?

    Rapport Therapeutics, Inc. Common Stock (RAPP) does not currently pay a regular dividend.

    What is RAPP's market cap?

    Rapport Therapeutics, Inc. Common Stock (RAPP) has a market capitalization of $1.36B with a current stock price of $29.57.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In